ENXTBR:ARGXBiotechs
Assessing Argenx (ENXTBR:ARGX) Valuation After FDA Priority Review Acceptance For VYVGART In Seronegative gMG
Argenx (ENXTBR:ARGX) is back in focus after the U.S. Food and Drug Administration accepted a priority review for a supplemental Biologics License Application for VYVGART in seronegative generalized myasthenia gravis.
See our latest analysis for argenx.
The FDA priority review has arrived after a year where argenx’s share price has been relatively muted in the short term, with a 30 day share price return of 2.45% decline and year to date share price return of 3.15% decline. However, the 1 year...